Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001999371-25-015943
Filing Date
2025-10-23
Accepted
2025-10-23 16:07:17
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 7585
  Complete submission text file 0001999371-25-015943.txt   9355
Mailing Address 111 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080
Business Address 111 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080 650-392-8412
SUTRO BIOPHARMA, INC. (Subject) CIK: 0001382101 (see all company filings)

EIN.: 452441988 | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-90656 | Film No.: 251413088
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address 450 PARK AVENUE SUITE 1403 NEW YORK NY 10022
Business Address 450 PARK AVENUE SUITE 1403 NEW YORK NY 10022 917-826-4533
Affinity Asset Advisors, LLC (Filed by) CIK: 0001773195 (see all company filings)

EIN.: 821567490 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G